Alessa Therapeutics, a clinical-stage drug development company pioneering an innovative and proprietary localized drug delivery technology for the early interception of cancer and other diseases, announced the closing of a $15M seed financing led by Mission BioCapital joined by Johnson & Johnson (through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc. (JJDC)., and a representative of JJDC will join the Board of Directors at Alessa Therapeutics Inc.
“We are appreciative of the support provided by this syndicate of leading life science industry investors,” said Pamela Munster, M.D., Founder & Chief Executive Officer of Alessa. “Alessa is well positioned to advance our pipeline and leverage our platform of tissue-targeted drug delivery for the treatment of prostate cancer and other solid organ diseases. This funding enables us to pursue our mission and bring new medicines to patients who desperately need more effective treatments.”
UCSF Congratulates our own principal investigator, Pamela Munster, PhD, for her company's success!